Zylox-Tonbridge Medical Technology Co., Ltd. Class H (2190) Price & Analysis

Compare

0 Followers

2190 Stock Chart & Stats

Day’s Range― - ―

52-Week RangeHK$9.41 - HK$17.40

Previous CloseN/A

Volume305.57K

Average Volume (3M)886.49K

Market Cap

€5.55B

Enterprise ValueHK$2.07B

Total Cash (Recent Filing)¥1.09B

Total Debt (Recent Filing)¥55.88M

Price to Earnings (P/E)50.7

Beta0.58

Next Earnings

Aug 20, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.33

Shares Outstanding322,400,760

10 Day Avg. Volume787,150

30 Day Avg. Volume886,485

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€18.64

Price Target Upside10.97% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

---

Zylox-Tonbridge Medical Technology Co., Ltd. Class H News

PremiumCompany Announcements

Zylox-Tonbridge Announces Board Meeting to Discuss Final Dividend

13d ago

PremiumCompany Announcements

Zylox-Tonbridge Announces Board Composition and Committee Roles

23d ago

PremiumCompany Announcements

Zylox-Tonbridge Announces Director Resignation

23d ago

PremiumRatings

Optimistic Buy Rating for Zylox-Tonbridge: Earnings and Sales Growth Drive Price Target Increase

1M ago

PremiumCompany Announcements

Zylox-Tonbridge Reports Significant Revenue Growth in 2024

1M ago

PremiumCompany Announcements

Zylox-Tonbridge Schedules Board Meeting to Approve 2024 Annual Results

2M ago

PremiumCompany Announcements

Zylox-Tonbridge Announces Change of Business Address in Hong Kong

3M ago

PremiumCompany Announcements

Zylox-Tonbridge Grants Share Awards to Boost Performance

4M ago

See All HK:2190 News

---

Financials

Quarterly

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

2.01%

Mutual Funds

― Other Institutional Investors

97.71% Public Companies and

Individual Investors

Detailed Ownership Overview >

2190 FAQ

What was Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s price range in the past 12 months?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H lowest stock price was HK$9.41 and its highest was HK$17.40 in the past 12 months.

What is Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s market cap?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s market cap is €5.55B.

When is Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s upcoming earnings report date?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s upcoming earnings report date is Aug 20, 2025 which is in 119 days.

How were Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s earnings last quarter?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H released its earnings results on Mar 20, 2025. The company reported HK$0.101 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.101.

Is Zylox-Tonbridge Medical Technology Co., Ltd. Class H overvalued?

According to Wall Street analysts Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Zylox-Tonbridge Medical Technology Co., Ltd. Class H pay dividends?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H does not currently pay dividends.

What is Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s EPS estimate?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Zylox-Tonbridge Medical Technology Co., Ltd. Class H have?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H has 322,400,760 shares outstanding.

What happened to Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s price movement after its last earnings report?

Zylox-Tonbridge Medical Technology Co., Ltd. Class H reported an EPS of HK$0.101 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.542%.

Which hedge fund is a major shareholder of Zylox-Tonbridge Medical Technology Co., Ltd. Class H?

Currently, no hedge funds are holding shares in HK:2190

---

Company Description

Zylox-Tonbridge Medical Technology Co., Ltd. Class H

Zylox-Tonbridge Medical Technology Co Ltd is committed towards the development and production of medical devices in the peripheral and neurointervention fields. It provides humanized medical services and advanced overall solutions for doctors and patients in China and overseas.

---

2190 Stock 12 Month Forecast

Average Price Target

HK$18.64

▲(10.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"HK$6","19":"HK$19","9.25":"HK$9.25","12.5":"HK$12.5","15.75":"HK$15.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18.600000002292266,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$18.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.6427373627,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$18.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.600000002292266,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$18.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,9.25,12.5,15.75,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2023","6":"Jun<br/>2023","9":"Sep<br/>2023","12":"Mar<br/>2025","25":"Mar<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.4,12.876923077099406,13.353846154198811,13.830769231298216,14.30769230839762,14.784615385497025,15.26153846259643,15.738461539695836,16.21538461679524,16.692307693894644,17.16923077099405,17.646153848093455,18.123076925192862,{"y":18.600000002292266,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.4,12.880210566361539,13.360421132723078,13.840631699084616,14.320842265446155,14.801052831807693,15.28126339816923,15.761473964530769,16.241684530892307,16.721895097253846,17.202105663615384,17.682316229976923,18.16252679633846,{"y":18.6427373627,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.4,12.876923077099406,13.353846154198811,13.830769231298216,14.30769230839762,14.784615385497025,15.26153846259643,15.738461539695836,16.21538461679524,16.692307693894644,17.16923077099405,17.646153848093455,18.123076925192862,{"y":18.600000002292266,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.22,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.84,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.2,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.8,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.9,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.64,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.26,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.54,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.74,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.5,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.84,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.84,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Similar Stocks

CSPC Pharmaceutical Group

―

TGRNF

Tong Ren Tang Technologies Co

―

WXIBF

Wuxi Biologics (Cayman)

―

1752

Top Education Group Ltd.

―

6826

Shanghai Haohai Biological Technology Co., Ltd. Class H

―

Compare HK:2190 Stocks >

Best Analysts Covering 2190

1 Year

Alexis YanMorgan Stanley

1 Year Success Rate

1/1 ratings generated profit

1 Year Average Return

+2.20%

reiterated a buy rating last month

Copying Alexis Yan's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +2.20% per trade.

Best Analyst Covering >

Popular Stocks

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing